Eli Lilly and Company has shown rapid growth with significant revenue increases. Click here to find out why I've decided to ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...

We recently published a list of 10 Stocks with Consistent Growth to Buy. In this article, we are going to take a look at ...

Eli Lilly said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, ...

UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly's treatment for early Alzheimer's, the ...

Dick Durbin (D-Ill.) demanded answers from Pfizer and Eli Lilly about their relationships with the telehealth prescribers ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) is having a terrific 2024. Shares have gained 58% so far this year, handily ...

Key Takeaways For Eli Lilly, the PE, PB, and PS ratios are all high compared to its peers in the Pharmaceuticals industry, indicating potentially overvalued stock. On the other hand, Eli Lilly's ...

A new Alzheimer’s treatment from US firm Eli Lilly was approved for use this week by the UK drug regulator MHRA, although disappointingly for its maker, the drug won’t be available on the NHS as it ...

Ahead of the event, analysts expect LLY to report a profit of $1.98 per share on a diluted basis, up significantly from $0.10 per share in the year-ago quarter. The company has consistently surpassed ...

Unfortunately, many of our elected leaders today undervalue the role of patents to progress the science of drug discovery and ...